PharmaShots Weekly Snapshots (October 10 - 14, 2022)
Bio-Thera Reports First Patient Dosing in P-I Study of BAT2606, a Proposed Biosimilar of Nucala (mepolizumab) for Severe Asthma
Published: Oct 14, 2022| Tags: Bio-Thera Solutions, BAT2606, Nucala, mepolizumab, Severe Asthma, Clinical Trial, P-I Study
Enliven Therapeutics Entered into a Definitive Merger Agreement with Imara for ~$594.1M
Published: Oct 14, 2022| Tags: Enliven Therapeutics, Merger Agreement, Imara, ELVN-002, ELVN-001, lung cancer, ~$574M, M&A
BridgeBio Pharma Presents P-I/II (CANaspire) Trial Results of BBP-812 for the Treatment of Canavan Disease at CNS 2022
Published: Oct 14, 2022| Tags: BridgeBio Pharma, BBP-812, Canavan Disease, Clinical Trial, P-I/II CANaspire Trial
GSK Reports P-III (AReSVi-006) Study Results of RSVPreF3 OA for the Treatment of Respiratory Syncytial Virus
Published: Oct 14, 2022| Tags: GSK, RSVPreF3 OA, Respiratory Syncytial Virus, Clinical Trial, P-III AReSVi-006 Study
AdAlta Collaborated with GPCR Therapeutics for Novel Therapies to Treat Cancer
Published: Oct 14, 2022| Tags: AdAlta, GPCR Therapeutics, Novel Therapies, Cancer, CXCR4-B2AR, AD-214, Pharma
Edgewise Therapeutics Reports 6-Month Interim (ARCH) Study Results of EDG-5506 for Becker Muscular Dystrophy
Published: Oct 14, 2022| Tags: Edgewise Therapeutics, EDG-5506, Becker Muscular Dystrophy, Clinical Trial, ARCH Study
Regeneron Reports the US FDA’s Acceptance of sBLA for Priority Review of Eylea to Treat Retinopathy of Prematurity
Published: Oct 13, 2022| Tags: Regeneron, Eylea, aflibercept, Retinopathy, Prematurity, Regulatory, US, FDA, sBLA, Priority Review
NanoString Collaborated with Visiopharm to Co-develop Integrated Workflows for Spatial Biology Solutions
Published: Oct 13, 2022| Tags: NanoString, Visiopharm, Integrated Workflows, GeoMx, AtoMx, Spatial Biology Solutions, Pharma
Pasithea Therapeutics Acquires AlloMek Therapeutics and Expands CNS-Focused Drug Development Pipeline
Published: Oct 13, 2022| Tags: Pasithea Therapeutics, AlloMek Therapeutics, CIP-137401, neurofibromatosis type 1, Noonan syndrome, Acquires, M&A
Astellas to Present P-III (SKYLIGHT 4) Study of Fezolinetant for Vasomotor Symptoms Associated with Menopause at NAMS 2022
Published: Oct 13, 2022| Tags: Astellas, Fezolinetant, Vasomotor Symptoms, Menopause, P-III, SKYLIGHT 4 Study, NAMS, 2022
Published: Oct 13, 2022| Tags: Tavros Therapeutics, Vividion Therapeutics, Oncology Programs, Pharma
Published: Oct 13, 2022| Tags: Pfizer, BioNTech, Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine, 10-µg, Booster, US, FDA, Emergency Use Authorization
BeiGene Reports P-III (ALPINE) Trial Results of Brukinsa (zanubrutinib) for the Treatment of Chronic Lymphocytic Leukemia
Published: Oct 12, 2022| Tags: BeiGene, Brukinsa, zanubrutinib, Chronic Lymphocytic Leukemia, Clinical Trial, P-III ALPINE Trial
Published: Oct 12, 2022| Tags: BridgeBio Pharma, BBP-398, Lumakras, sotorasib, Non-Small Cell Lung Cancer, Clinical Trial, P-I/II Trial
Gilead Reports the US FDA's Acceptance of Trodelvy's sBLA for Priority Review to Treat Pre-Treated HR+/HER2- Metastatic Breast Cancer
Published: Oct 12, 2022| Tags: Gilead, Trodelvy, HR+/HER2- Metastatic Breast Cancer, regulatory, sBLA, Priority Review, US, FDA
Published: Oct 12, 2022| Tags: Genentech, Evrysdi, risdiplam, Spinal Muscular Atrophy, WMS, 2022, Clinical Trial, JEWELFISH Study
AstraZeneca Entered into a Research Collaboration with Illumina to Accelerate AI-based Drug Target Discovery
Published: Oct 12, 2022| Tags: AstraZeneca, Illumina, AI-based Drug Target Discovery, PrimateAI, SpliceAI
Eli Lilly Entered into a Research Collaboration and License Agreement with Nimbus Therapeutics for Small Molecule Activators of AMPK
Published: Oct 12, 2022| Tags: Eli Lilly, Nimbus Therapeutics, Small Molecule Activators, AMPK, metabolic disorders
Published: Oct 11, 2022| Tags: HanAll, CSPC, NBP Pharma, Batoclimab, HL161BKN, HL036, tanfanercept, dry eye disease
Regeneron Presents P-III Trial Results of Dupixent (dupilumab) for Eosinophilic Esophagitis in Children Aged 1 to 11 Years at UEG 2022
Published: Oct 11, 2022| Tags: Regeneron, Dupixent, dupilumab, Eosinophilic Esophagitis, P-III Trial, UEG, 2022
JW Therapeutics Receives the NMPA’s Approval for Carteyva (relmacabtagene autoleucel) sNDA to Treat Relapsed or Refractory Follicular Lymphoma
Published: Oct 11, 2022| Tags: JW Therapeutics, Carteyva, relmacabtagene autoleucel, sNDA, Follicular Lymphoma, NMPA Approval, Regulatory
Brainomix Collaborated with UK Government-Funded NCIMI for AI-Powered Technology in Lung Cancer
Published: Oct 11, 2022| Tags: Brainomix, NCIMI, AI-Powered Technology, e-ACT, Lung Cancer, MedTech
Published: Oct 11, 2022| Tags: Merck, Sotatercept, Pulmonary Arterial Hypertension, Clinical Trial, P-III STELLAR Trial
Janssen Presents P-III (UNIFI) Study Results of Stelara (ustekinumab) for Active Ulcerative Colitis at UEG 2022
Published: Oct 11, 2022| Tags: Janssen, Stelara, ustekinumab, Active Ulcerative Colitis, P-III UNIFI Study, UEG, 2022
Janssen Presents P-IIa (VEGA) PoC Study Results of Guselkumab + Golimumab for Active Ulcerative Colitis at UEG 2022
Published: Oct 10, 2022| Tags: Janssen, Guselkumab, Golimumab, Active Ulcerative Colitis, P-IIa (VEGA) PoC Study, Clinical Trials, UEG, 2022
BIOCORP Signs an Agreement with Merck KGaA to Co-develop New Bluetooth-Enabled Drug Delivery Device
Published: Oct 10, 2022| Tags: BIOCORP, Merck KGaA, New Bluetooth-Enabled Drug Delivery Device, Mallya devices, Sanofi, Novo Nordisk, DigiHealth
Published: Oct 10, 2022| Tags: Ascletis, Multiple-Dose Escalation, P-I Clinical Trial, ASC10, COVID-19
Pfizer and BioNTech’s Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster Receives Health Canada Authorization in Individuals Aged ≥12 Years
Published: Oct 10, 2022| Tags: Pfizer, BioNTech, Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine, Health Canada, Authorization, Regulatory
Innovent’s Cyramza (ramucirumab) Receives NMPA’s Approval for the Treatment of Hepatocellular Carcinoma
Published: Oct 10, 2022| Tags: Innovent, Cyramza, ramucirumab, Hepatocellular Carcinoma, Regulatory, NMPA Approval
Published: Oct 10, 2022| Tags: Sciwind Biosciences, XW014, Obesity, Type 2 Diabetes, Clinical Trial, US
Related Post: PharmaShots Weekly Snapshots (October 03 - 07, 2022)
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
